Blue Moon Group Holdings Limited

Blue Moon Group Holdings Limited engages in the research, design, development, manufacture, and sale of personal hygiene, home care, and fabric care products in China. It offers fabric care products, including machine wash laundry, pre-wash treatment, underwear laundry, hand wash, strain removers, and fabric softeners, as well as baby liquid laundry detergents; personal hygiene products comprising liquid soaps; toilet and bathroom cleaners; and general home care products, such as anti-mould cleansers, washing machine cleaners, floor cleaners, bleaches, glass cleaners, multi-surface cleaners, and rust cleaners; and antiseptic disinfectant liquids. The company also provides kitchen cleaning products, including utensil, fruit, and vegetable cleaning products, as well as range of hood cleaners. The company offers its products under the Blue Moon, Supreme, Jingxiang, and Tianlu brands. It sells its products through e-commerce platforms, online stores, hypermarkets, supermarkets, and offline distributors. The company was founded in 1992 and is headquartered in Guangzhou, China.

Blue Moon Group Holdings Limited trades as BLUMY on OTC. The company is classified in Consumer Defensive / Household & Personal Products and reports in USD.

The current profile places the business in Household & Personal Products. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $8.39B of revenue and -$328.37M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Blue Moon Group Holdings Limited can be compared against peers such as Société BIC S.A., P/F Bakkafrost, Coca-Cola Bottlers Japan Holdings Inc., Ebro Foods, S.A., Kobayashi Pharmaceutical Co., Ltd., Lion Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2.01B, beta of 0.36, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BLUMY currently shows total debt of $84.90M and beta of 0.36. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.bluemoon.com.cn

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.